Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET

Company Participants

Nichol Ochsner - Vice President of Investor Relations

Richard Pascoe - CEO

LaDuane Clifton - Chief Financial Officer

Travis Mickle - President and Co-Founder

Christal Mickle - Chief Product Development Officer and Co-Founder

Joshua Schafer - Chief Commercial Officer and Executive Vice President, Business Development

Conference Call Participants

Jonathan Aschoff - ROTH MKM Partners

Louise Chen - Cantor Fitzgerald

Oren Livnat - H.C. Wainwright

Operator

Good day, and welcome to the Zevra Therapeutics Fourth Quarter and Full Year 2022 Update Call. [Operator Instructions] Please be advised that today's call is being recorded.

I want to hand the call over to Zevra's Vice President of Investor Relations and Corporate Communications, Nichol Ochsner. Thank you. You may begin.

Nichol Ochsner

Good morning. Thank you for joining us today to review Zevra's Fourth quarter and full year 2022 clinical operational progress and financial results. A few housekeeping items before we start. I invite you to view the webcast slides and the press release, both of which were issued this morning and can be found in the Investors section of our website.

As outlined on Slide 2, during today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to, the clinical and regulatory path for arimoclomol, AZSTARYS, revenue milestones and expected revenue from the French EAP program, the planned next steps in our pipeline programs; the timing for enrollment, initiation, the completion and reporting of data from our clinical trials and the upcoming Annual Meeting of Stockholders. These statements are neither promises nor guarantees and involve risks and uncertainties and other important factors that may cause actual results to differ materially from those discussed here. Important factors that could cause actual results to differ from forward-looking statements can be found in the Risk Factors section of our annual report on Form 10-K for the full year ended December 31, 2022, expected to be filed with the SEC today.

Finally, you can view the agenda for today's call on Slide 3. I'm pleased to welcome Zevra's management team members participating in today's call. I'm joined today by our CEO, Richard Pascoe; our President and Co-Founder, Dr. Travis Mickle; our Chief Financial Officer, LaDuane Clifton; our Chief Product Development Officer and Co-Founder, Christal Mickle; and Joshua Schafer, Chief Commercial Officer and Executive Vice President, Business Development.